Equities

Bellevue Life Sciences Acquisition Corp

BLAC:NAQ

Bellevue Life Sciences Acquisition Corp

Actions
FinancialsOpen End and Miscellaneous Investment Vehicles
  • Price (USD)11.05
  • Today's Change0.00 / 0.00%
  • Shares traded5.00
  • 1 Year change+5.94%
  • Beta--
Data delayed at least 15 minutes, as of Nov 05 2024 19:14 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments0.020.120.00
Total Receivables, Net------
Total Inventory------
Prepaid expenses0.01----
Other current assets, total------
Total current assets0.020.120.00
Property, plant & equipment, net------
Goodwill, net------
Intangibles, net------
Long term investments37----
Note receivable - long term------
Other long term assets------
Total assets371.230.71
LIABILITIES
Accounts payable------
Accrued expenses0.360.010.29
Notes payable/short-term debt01.200.40
Current portion long-term debt/capital leases------
Other current liabilities, total0.600.020.01
Total current liabilities2.041.260.71
Total long term debt000
Total debt01.200.40
Deferred income tax2.07----
Minority interest------
Other liabilities, total------
Total liabilities4.111.260.71
SHAREHOLDERS EQUITY
Common stock360.000.00
Additional paid-in capital00.020.02
Retained earnings (accumulated deficit)(3.91)(0.06)(0.03)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity33(0.04)0.00
Total liabilities & shareholders' equity371.230.71
Total common shares outstanding5.629.067.93
Treasury shares - common primary issue--00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.